Company has generated strong operating cash flow, which enabled reduction of debt and is expected to deliver better results going forward. Company's focus is to strengthen the balance sheet, invest in strategic opportunities without increasing debt levels and build strong pipeline or products across its businesses.

Strong fundamentals, superior growth in specialty pharmaceuticals and LSI, reduction in debt coupled with renewed focus on the allergy business & strong order book in CMO, helps company to outperform industry growth, expand its market share and provides sufficient business visibility, going forward.